Press releaseGlobe Newswire
Madrigal Pharmaceuticals
MDGL · NASDAQ
$467.54+$20.45 (+4.57%)TodayMarket closed ·
Prev close $447.09
Latest news
- NewsErica Kollmann
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
- Press releaseGlobe Newswire
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
- Press releaseGlobe Newswire
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
- News
4 Health Care Stocks With Whale Alerts In Today’s Session
- Press releaseGlobe Newswire
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
- Press releasePRNewswire
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
- Press releaseGlobe Newswire
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
- Press releaseGlobe Newswire
Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
- News
Earnings Scheduled For May 6, 2026
- News
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
- Press releaseGlobe Newswire
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
- Press releaseBusiness Wire
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
- Press releaseGlobe Newswire
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
- Press releasePRNewswire
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
- Press releasePRNewswire
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
- News
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
- News
Earnings Scheduled For February 19, 2026
- News
Earnings Preview For Madrigal Pharmaceuticals
- Press releasePRNewswire
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
- News
10 Analysts Have This To Say About Madrigal Pharmaceuticals
- NewsNabaparna Bhattacharya
Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releasePRNewswire
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
- NewsNabaparna Bhattacharya
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?
- News
Earnings Scheduled For November 4, 2025
- News
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast
- News
Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock
- NewsVandana Singh
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
- NewsVandana Singh
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
- News
Earnings Scheduled For August 5, 2025
- NewsVandana Singh
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
- News
5 Health Care Stocks With Whale Alerts In Today's Session
- News
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
- NewsAvi Kapoor
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday
- News
10 Health Care Stocks Whale Activity In Today's Session
- NewsLekha Gupta
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
Earnings Preview For Madrigal Pharmaceuticals
- News
10 Health Care Stocks With Whale Alerts In Today's Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.